Navigation Links
Common Diabetes Drug May Fight Cancer

Metformin-chemo combination shrinks tumors, delays recurrence in mice: study

MONDAY, Sept. 14 (HealthDay News) -- Adding the widely used diabetes drug metformin to conventional chemotherapy shows promise for treating and delaying recurrence of breast cancer, new research suggests.

In lab tests using mice with breast cancer, researchers found that the drug combination suppressed the cancer stem cells thought to drive tumor progression.

"We discovered that metformin selectively kills cancer stem cells. Very few compounds do that," said Kevin Struhl, lead researcher of a paper appearing in the Sept. 14 online early edition of Cancer Research.

Stem cells are resistant to chemotherapy, and scientists had hoped to find a compound that kills them. "The basic idea in the stem cell hypothesis is that standard chemotherapy can kill the cancer cells that make up the bulk of the tumor, but it's not getting the stem cells, so they re-grow and the tumor comes back. That's a classic pattern," said Struhl, a professor of biological chemistry and molecular pharmacology at Harvard Medical School.

That metformin is a known compound adds to the good news. "The exciting thing was that they found an old and relatively safe compound and showed that it had a property that was selectively toxic to cancer stem cells," said Dr. Jonathan Chernoff, deputy scientific director at Fox Chase Cancer Center in Philadelphia. "That's new."

Metformin, which is marketed under the brand names Glucophage, Riomet, Fortamet, Glumetza, Obimet, Dianben and Diabex, is an agent that makes the body more sensitive to insulin. Over decades, millions of people have taken it.

"It's known that diabetics who take metformin have a much lower cancer incidence than diabetics who don't, so there has been a hint that the drug might be useful," said Struhl.

One recent study found that metformin may lower a diabetic patient's risk of developing pancreatic cancer by as much as 60 percent.

What was unclear was whether metformin helps diabetics deal better with their blood sugar levels and insulin sensitivity or whether it affects the cancer itself. The results of this study point strongly to the latter.

Mice in this study that simultaneously received metformin and doxorubicin, a common chemotherapy agent, showed reductions in tumor size in four types of breast cancer, as well as longer remission times.

On its own, metformin, which was given in lower doses than normal for diabetics, did not have such a striking effect, indicating that the two treatments in combination are key.

Scientists hope that the metformin-chemo combination will result in a need for less chemo, thereby reducing painful side effects.

"Basically the [current] chemo dose is set up to give you as much as you can possibly tolerate on the grounds that the more you kill, the better it is, but likely you're overdoing to do that," Struhl said. "If you could cut [chemotherapy] in half, for example, and use metformin, you might get equally good clinical results and cut side effects."

Researchers also hope that the metformin protocol could have similar synergistic effects in other types of cancers.

Although it's always wise to be cautious when interpreting studies done in mice, "some of the cells they were testing were actually of human origin, so even though they were tested for tumorigenicity in mice, it still has some relevance," Chernoff said.

Researchers are planning clinical trials, which will be the "ultimate test," Struhl said.

Researchers may also start looking at other drugs for similar effects. If other known drugs with good safety profiles prove effective, "that would be an incredible thing," Chernoff said.

More information

Read more about stem cells at the National Institutes of Health.

SOURCES: Kevin Struhl, Ph.D., the David Wesley Gaiser professor of biological chemistry and molecular pharmacology, Harvard Medical School, Boston; Jonathan Chernoff, M.D., Ph.D., deputy scientific director, Fox Chase Cancer Center, Philadelphia; Sept. 14, 2009, Cancer Research

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
Related Image:
Common Diabetes Drug May Fight Cancer
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology: